Intellia Therapeutics has seen its stock fall sharply over several years, even as the business moves closer to potential commercialization of its gene editing therapies. This raises a clear question about whether the current share price is properly anchored to its sales base.

• Over the past 5 years, the share price has fallen 91.3%, which puts the focus squarely on what investors are now paying for each dollar of Intellia Therapeutics' revenue.

• Progress in late stage programs for hereditary angioedema and transthyretin amyloidosis, along with preparations for a possible first U.S. launch, can shift expectations for future sales scale and the timing of cash inflows that feed into valuation multiples.

• Your read on Intellia Therapeutics is one view; the desks covering it have another. See what analysts think Intellia Therapeutics's shares could be worth .

The issue now is whether Intellia Therapeutics' current US$11.42 share price is justified by its sales when compared with the Fair Ratio benchmark.

If you are weighing Intellia Therapeutics against other opportunities that focus on valuation and fundamentals, it can help to compare it with companies in the 33 high quality undervalued stocks .

Has Intellia Therapeutics Run Too Far on Sales?

P/S is often the cleaner yardstick for Intellia Therapeutics because earnings are still negative and the story is about potential commercial revenue, not current profits. On this measure, the stock trades on a P/S of about 26.9x, compared with roughly 11.2x for the broader biotechs industry and 25.5x for closer peers. That places Intellia on a clear premium to the sector and slightly above the peer pack.

Despite recent Phase 3 progress and pre launch work around LVOSI and Nexi, the valuation model's Fair Ratio screens the shares as overvalued on this framework and flags an extreme gap to what it suggests would be a more grounded multiple. The model is heavily penalising ongoing losses and execution risk, so the signal here is less about a precise target and more about how much optimism is already embedded in today's P/S tag. Readers weighing Intellia Therapeutics against other biotech stocks may want to consider how much confidence they place in eventual commercial uptake relative to this premium. Explore the numbers behind Intellia Therapeutics's P/S valuation .

The Intellia Therapeutics Narrative: What Would Justify Today's Price?

Narratives on Simply Wall St's Community page pick up where this valuation puzzle for Intellia Therapeutics' P/S ratio leaves off and spell out which growth, margin and earnings paths would need to play out for the shares to look meaningfully higher or lower than today's quote. Each one treats fair value as a concrete, testable view on how the business might develop over time, so you can watch whether that story still holds up as new information arrives.